Literature DB >> 28699646

Review of Opioid Pharmacogenetics and Considerations for Pain Management.

Aniwaa Owusu Obeng1,2,3, Issam Hamadeh4, Michael Smith5.   

Abstract

Opioid analgesics are the standards of care for the treatment of moderate to severe nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties mainly emanate from stimulation of the μ receptors, which are encoded by the OPRM1 gene. Hepatic metabolism represents the major route of elimination, which, for some opioids, namely codeine and tramadol, is necessary for their bioactivation into more potent analgesics. The highly polymorphic nature of the genes coding for phase I and phase II enzymes (pharmacokinetics genes) that are involved in the metabolism and bioactivation of opioids suggests a potential interindividual variation in their disposition and, most likely, response. In fact, such an association has been substantiated in several pharmacokinetic studies described in this review, in which drug exposure and/or metabolism differed significantly based on the presence of polymorphisms in these pharmacokinetics genes. Furthermore, in some studies, the observed variability in drug exposure translated into differences in the incidence of opioid-related adverse effects, particularly nausea, vomiting, constipation, and respiratory depression. Although the influence of polymorphisms in pharmacokinetics genes, as well as pharmacodynamics genes (OPRM1 and COMT) on response to opioids has been a subject of intense research, the results have been somehow conflicting, with some evidence insinuating for a potential role for OPRM1. The Clinical Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic recommendations to individualize treatment with tramadol and codeine. However, implementation guidelines for other opioids, which are more commonly used in real-world settings for pain management, are currently lacking. Hence, further studies are warranted to bridge this gap in our knowledge base and ultimately ascertain the role of pharmacogenetic markers as predictors of response to opioid analgesics.
© 2017 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  efficacy; opioids; personalized dosing; personalized pain management; pharmacogenetics; safety; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28699646     DOI: 10.1002/phar.1986

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  25 in total

Review 1.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

2.  Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study.

Authors:  Andrea Iaboni; Michael A Campitelli; Susan E Bronskill; Christina Diong; Matthew Kumar; Laura C Maclagan; Tara Gomes; Mina Tadrous; Colleen J Maxwell
Journal:  CMAJ Open       Date:  2019-09-23

3.  A pathway-driven predictive model of tramadol pharmacogenetics.

Authors:  Frank R Wendt; Nicole M M Novroski; Anna-Liina Rahikainen; Antti Sajantila; Bruce Budowle
Journal:  Eur J Hum Genet       Date:  2019-03-01       Impact factor: 4.246

Review 4.  Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature.

Authors:  Belinda Coronado; Jacob Dunn; Michael A Veronin; Justin P Reinert
Journal:  J Pharm Technol       Date:  2021-04-19

5.  Causal Effect of Chronic Pain on Mortality Through Opioid Prescriptions: Application of the Front-Door Formula.

Authors:  Kosuke Inoue; Beate Ritz; Onyebuchi A Arah
Journal:  Epidemiology       Date:  2022-04-05       Impact factor: 4.860

6.  Reducing Opioid Prescriptions by Identifying Responders on Topical Analgesic Treatment Using an Individualized Medicine and Predictive Analytics Approach.

Authors:  Jeffrey Gudin; Seferina Mavroudi; Aigli Korfiati; Konstantinos Theofilatos; Derek Dietze; Peter Hurwitz
Journal:  J Pain Res       Date:  2020-05-28       Impact factor: 3.133

Review 7.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.

Authors:  Kristine R Crews; Andrew A Monte; Rachel Huddart; Kelly E Caudle; Evan D Kharasch; Andrea Gaedigk; Henry M Dunnenberger; J Steven Leeder; John T Callaghan; Caroline Flora Samer; Teri E Klein; Cyrine E Haidar; Sara L Van Driest; Gualberto Ruano; Katrin Sangkuhl; Larisa H Cavallari; Daniel J Müller; Cynthia A Prows; Mohamed Nagy; Andrew A Somogyi; Todd C Skaar
Journal:  Clin Pharmacol Ther       Date:  2021-02-09       Impact factor: 6.903

8.  Rubiscolin-6 activates opioid receptors to enhance glucose uptake in skeletal muscle.

Authors:  Timothy Sean Kairupan; Kai-Chun Cheng; Akihiro Asakawa; Haruka Amitani; Takakazu Yagi; Koji Ataka; Natasya Trivena Rokot; Nova Hellen Kapantow; Ikuo Kato; Akio Inui
Journal:  J Food Drug Anal       Date:  2018-08-14       Impact factor: 6.157

9.  Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort.

Authors:  Earl B Ettienne; Adaku Ofoegbu; Mary K Maneno; Jayla Briggs; Ginikannwa Ezeude; Simisola Williams; Casey Walker; Edwin Chapman
Journal:  J Natl Med Assoc       Date:  2019-10-31       Impact factor: 1.798

10.  Is otologic surgery contributing to the opioid epidemic?

Authors:  Valerie Dahm; Justin T Lui; Rudolfs Liepins; Joseph M Chen; Trung N Le; Christoph Arnoldner; Vincent Y W Lin
Journal:  J Otolaryngol Head Neck Surg       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.